What is Corcept Therapeutics's latest dividend and current dividend yield?

What factors drove the changes in Corcept Therapeutics's revenue and profit?

What guidance did Corcept Therapeutics's management provide for the next earnings period?

What were the key takeaways from Corcept Therapeutics's earnings call?

What were the key takeaways from Corcept Therapeutics’s earnings call?

What is the market's earnings forecast for Corcept Therapeutics next quarter?

Did Corcept Therapeutics beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Corcept Therapeutics year over year?

- **Revenue Growth**: 2025 revenue $761M (+13% YoY); 2026 guidance $900-1B.
- **Legal Battles**: Federal Circuit ruled against generic Korlym; FDA denied relacorilant NDA.
- **Cushing's Business**: 61% new prescriptions YoY; 37% tablet growth post pharmacy transition.
- **Oncology Success**: ROSELLA trial showed 35% OS improvement in ovarian cancer.
- **Pipeline Momentum**: DAZZLE ALS trial 84% mortality risk reduction; MONARCH MASH trial enrollment complete.

**【CFO Opening Remarks】**
- 2025 revenue: $761 million (13% YoY growth) with 2026 guidance of $900-1 billion.
- Net income: $99.7 million; cash: $532 million post $245 million stock buyback.
- Transitioned to new specialty pharmacy in Q4 2025 to address prior supply chain bottlenecks.

**【Legal Update】**
- Federal Circuit ruled against Corcept in Teva generic Korlym litigation; appeal planned.
- FDA denied relacorilant NDA for Cushing's syndrome citing liver enzyme elevations; meeting scheduled for April 2026.
- 2025 spent $245 million on stock buybacks under $1 billion repurchase program.

**【Business Performance】**
- Cushing's syndrome prescriptions up 61% YoY; tablets sold +37% despite pharmacy transition.
- New specialty pharmacy achieved record Feb 2026 patient starts; 78% AG prescriptions vs. 30% Korlym net price discount.
- Catalyst trial showed 1.47% HbA1c improvement vs. 0.17% placebo; 24% diabetes patients had hypercortisolism.

**【CEO Vision】**
- ROSELLA trial met dual endpoints: 35% OS improvement (p=0.0004) and 3.1-month PFS benefit in ovarian cancer.
- Phase II DAZZLE trial showed 84% mortality risk reduction in ALS (p=0.0009).
- MONARCH trial for metabolic dysfunction-associated steatohepatitis (MASH) fully enrolled; results Q4 2026.

**【Q&A Highlights】**
- Supply chain: New pharmacy resolved 2025 bottlenecks; Feb 2026 new starts near record levels.
- FDA: April 2026 meeting to discuss relacorilant; no new safety signals in ROSELLA vs. paclitaxel alone.
- Oncology adoption: 35% OS improvement in platinum-resistant ovarian cancer vs. 10% KEYTRUDA response rate.
- Pricing: AG net price ~30% of Korlym; stable at 78% of prescriptions vs. 2024's 60%.

Corcept Therapeutics Incorporated(CORT)-20260225-2025 Q4 Earnings call transcript

- **Revenue Growth**: Q3 2025 revenue $207.6M (+19% YoY); 2025 guidance $800M-$850M
- **FDA Milestones**: relacorilant approvals expected Dec 2025 (hypercortisolism), Jul 2026 (ovarian cancer)
- **Patient Expansion**: 3,250 active Korlym patients (+42% YoY); transitioning to new pharmacy network
- **Oncology Breakthrough**: ROSELLA trial shows relacorilant + nab-paclitaxel improves ovarian cancer survival
- **Future Potential**: $3B-$5B annual target for relacorilant; Phase III ALS trial planned for 2026

**【CFO Financial Remarks】**
- Q3 2025 revenue: $207.6M (19% YoY growth); updated 2025 guidance: $800M-$850M
- Net income: $19.7M (45% YoY decline); cash & investments: $524M (includes $50M stock buyback)
- Gross margin remains stable despite 75% of sales on authorized generic (30% discount to Korlym list price)

**【Patent Litigation Update】**
- Ongoing appeal against Teva's generic Korlym; Federal Circuit decision pending
- If successful, Teva's generic would lose FDA approval until 2037 patent expiry

**【Endocrinology Division Update】**
- Korlym prescriptions up 42% YoY; 3,250 active patients at Q3 end
- Transitioning to new pharmacy (Curant) with 25+ years of orphan drug experience
- Planning to add 2 more pharmacies by Q1 2026 to handle relacorilant launch

**【CEO Strategic Overview】**
- Key FDA dates: relacorilant for hypercortisolism (Dec 30, 2025 PDUFA); ovarian cancer (Jul 11, 2026)
- CATALYST trial shows 25% of diabetic patients have hypercortisolism; Korlym reduces HbA1c by 1.47% vs placebo
- $3B-$5B annual revenue target for relacorilant in hypercortisolism

**【CDO Oncology Pipeline】**
- Ovarian cancer: ROSELLA trial shows relacorilant + nab-paclitaxel improves PFS & OS
- New studies launching: 
  - BELLA trial (relacorilant + bevacizumab in platinum-sensitive ovarian)
  - Phase II in endometrial & cervical cancers
  - Phase Ib with PD-1 inhibitor nivolumab
- ALS Phase III planned for mid-2026 after DAZALS trial showed 84% mortality risk reduction

Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript

- **Revenue Growth Strong:** Q2 revenue $194.4M (+19% YoY), guided to $850-900M for 2025.
- **Hyper Cortisolism Expansion:** CATALYST trial results driving 49% tablet growth; relacorilant projected to generate $3-5B annually.
- **Ovarian Cancer Breakthrough:** ROSELLA trial shows 30% PFS improvement, NDA filed with PDUFA 12/30/25.
- **Pipeline Momentum:** ALS survival benefit (84% death risk reduction), NASH Phase IIb trial, and prostate cancer combo trials.
- **Key Risk:** Pharmacy capacity constraining near-term growth, resolved by Q4 2025.

**【CFO Financial Remarks】**
- Q2 2025 revenue: $194.4 million (19% YoY growth). Updated 2025 guidance: $850-900 million.
- Net income: $35.1 million (stable YoY). Cash balance: $515 million post $115 million share buyback.
- Key driver: Endocrinology division growth, offset by AG pricing discounts (30% avg vs. Korlym list price).

**【Endocrinology Division Update】**
- Korlym tablets shipped +49% YoY; Q2 revenue growth underperformed due to pharmacy capacity constraints (-$15M impact).
- New prescribers/prescriptions at record highs; CATALYST trial results driving awareness (1 in 4 diabetic patients with hypercortisolism).
- Transitioning to AG: 67% of business now on AG, stabilizing at ~70% by year-end.
- Second pharmacy onboarding Q4 to support relacorilant launch (PDUFA 12/30/25).

**【Patent Litigation Update】**
- Federal Circuit oral argument (7/7/25) on Teva generic Korlym infringement; decision expected Q3-Q4.
- If upheld, Teva approval blocked until 2037 patent expiry.
- Company confident in legal position, prioritizing resolution.

**【CEO Strategic Update】**
- **Hyper Cortisolism:**
  - CATALYST trial shows Korlym reduces HbA1c by 1.47% vs. 0.15% placebo (p<0.001). Relacorilant NDA supported by GRACE/GRADIENT trials.
  - Projected $3-5B annual relacorilant revenue in hypercortisolism by 2030.
- **Ovarian Cancer:**
  - ROSELLA trial: relacorilant + nab-paclitaxel reduces progression risk by 30% (HR 0.7, p=0.008) and extends OS to 16 vs. 11.5 months (p=0.01).
  - NDA filed; targeting $1B+ annual revenue in oncology.
- **Pipeline Expansion:**
  - ALS: DAZALS trial shows 84% reduction in death risk at 12 months (p=0.0009).
  - NASH: Phase IIb MONARCH trial enrolling; miricorilant shows rapid liver fat reduction.
  - Prostate cancer: Phase II trial with enzalutamide evaluating cortisol receptor antagonism.

**【Q&A Highlights】**
- **Supply Chain:**
  - Q2 pharmacy capacity improved but still lagging demand. Second pharmacy to contribute Q4.
  - Prescribe-to-fill gap narrowed but remains significant (~$15M Q2 impact).
- **Litigation Risk:**
  - No material impact on $3-5B hypercortisolism forecast if Teva appeal fails.
- **Oncology Expansion:**
  - BELLA trial enrolling for platinum-sensitive ovarian cancer. Exploring combinations with immunotherapy/ADCs.
- **ALS Regulatory Path:**
  - FDA meeting scheduled for August to discuss potential accelerated approval or confirmatory trial design.

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

- **Revenue growth acceleration**: Q1 2025 revenue up 12.7% YoY to $157.2M, guided to $900-950M for 2025.
- **Korlym momentum**: Prescriptions up 97% YoY, CATALYST study shows 25% of diabetics have hypercortisolism.
- **Oncology breakthrough**: Relacorilant improves PFS by 30% and OS by 40% in ovarian cancer, NDA expected Q4 2025.
- **Pipeline expansion**: 5+ Phase 2+ programs in ALS, liver disease, and solid tumors.
- **Operational fix**: Pharmacy capacity issues resolved, tablets dispensed up 200% QoQ in Q1.

**【CFO Financial Summary】**
- Q1 2025 revenue: $157.2M (12.7% YoY growth), reiterating 2025 guidance of $900-950M.
- Net income: $20.5M (26.3% YoY decline), driven by higher R&D expenses.
- Cash & investments: $570.8M, with $43M in share buybacks.

**【Endocrinology Division Update】**
- Korlym prescriptions +97% YoY, new prescribers +108% YoY.
- CATALYST study: 25% of poorly controlled diabetics have hypercortisolism; Korlym reduced HbA1c by 1.47% vs. 0.15% placebo (p<0.0001).
- Pharmacy vendor capacity issues resolved in March/April, tablets dispensed up 200% QoQ.

**【Oncology Pipeline Highlights】**
- Relacorilant (ovarian cancer): Phase 3 ROSELLA showed 30% PFS improvement (HR 0.70, p=0.008) and 40% OS improvement (HR 0.69, p=0.01).
- Phase 2b BELLA trial combining with bevacizumab underway.
- ALS program: Dazucorilant showed 6x survival benefit in 300mg arm (HR 0.16, p=0.0009).
- MASH program: Miricorilant reduced liver fat 30% in Phase 1b, Phase 2b MONARCH enrolling.

**【Key Q&A Takeaways】**
- Pharmacy vendor scaled staffing to handle +150% QoQ volume; no bolus expected, growth will be steady.
- Relacorilant positioned as first-line for platinum-resistant ovarian cancer, ahead of Elahere.
- FDA advisory committee unlikely for hypercortisolism NDA; oncology NDA expected Q4 2025.
- ALS program seeking regulatory feedback on accelerated approval path.


Corcept Therapeutics (CORT)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue surge**: 40% YoY growth to $675M, 2025 guided to $900-950M
- **Relacorilant breakthrough**: Phase III shows 6x better BP control, 6-year durability
- **Ovarian cancer hope**: ROSELLA trial dual endpoints with 20% survival benefit
- **Market expansion**: $3-5B market by 2030 as 1/4 diabetics diagnosed with hypercortisolism

**【CFO Financial Summary】**
- 2024 revenue: $675 million (40% YoY growth)
- 2025 revenue guidance: $900-950 million
- Net income: $141 million (33% YoY growth)
- Cash and investments: $603 million (up from $425 million)
- Stock buybacks: $38 million in 2024

**【Legal Update】**
- Ongoing patent litigation against Teva
- Federal Circuit appeal pending
- Oral argument expected May 2025, decision 3-4 months later
- If successful, Teva product would lose FDA approval until 2037

**【CEO Business Overview】**
- Korlym: Record Q4 prescribers and patients
- Relacorilant NDA submitted Dec 2024
  - GRACE Phase III: 152 patients, 6x better BP control vs placebo
  - Long-term extension: 6-year durability of cardiometabolic benefits
- Ovarian cancer trial (ROSELLA): 381 pts, PFS endpoint expected Q2
- ALS trial: 249 pts, 300mg dose showed 20% survival benefit
- MASH trial (miricorilant): 30% liver fat reduction, no GI side effects

**【Clinical Trial Updates】**
- ROSELLA: Dual primary endpoints (PFS & OS) with 0.04/0.01 p-values
- CATALYST: 1/4 diabetics have hypercortisolism, Korlym reduced HbA1c by 1.47%
- MOMENTUM study launching Q2 to assess hypertension prevalence

**【Analyst Q&A Highlights】**
- NDA timeline: FDA 60-day review period ending soon
- ROSELLA statistical design: 2 shots on goal (PFS/OS), alpha recycling
- Market growth: $3-5 billion by 2030 driven by hypercortisolism awareness
- Korlym supply chain issues resolved for 2025 growth

Actual											0.25	0.23	0.17	0.2	0.18	0.21	0.24	0.26	0.2	0.24	0.3	0.14	0.14	0.25	0.28	0.28	0.25	0.32	0.41	0.26	0.17	0.29	0.16	0.2
Forecast											0.2217	0.2225	0.21	0.165	0.2167	0.165	0.215	0.225	0.2317	0.2367	0.234	0.2397	0.1986	0.15	0.2183	0.2581	0.22	0.23	0.2819	0.4263	0.1425	0.1875	0.1637	0.3295
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+12.76%	+3.37%	-19.05%	+21.21%	-16.94%	+27.27%	+11.63%	+15.56%	-13.68%	+1.39%	+28.21%	-41.59%	-29.51%	+66.67%	+28.26%	+8.49%	+13.64%	+39.13%	+45.44%	-39.01%	+19.30%	+54.67%	-2.26%	-39.30%

Actual	--	--	--	--	--	--	--	--	--	--	93.25M	88.56M	86.33M	85.70M	79.44M	91.59M	96.13M	98.82M	93.69M	103.39M	101.73M	103.06M	105.65M	117.72M	123.60M	135.41M	146.81M	163.80M	182.55M	181.89M	157.21M	194.43M	207.64M	202.13M
Forecast	--	--	--	--	--	--	--	--	--	--	87.00M	90.13M	90.87M	90.36M	91.81M	86.84M	97.19M	100.57M	98.88M	101.00M	107.57M	105.08M	104.89M	109.60M	119.71M	129.27M	141.19M	155.14M	171.97M	198.74M	177.93M	199.39M	223.16M	256.88M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.17%	-1.74%	-5.00%	-5.16%	-13.47%	+5.47%	-1.09%	-1.74%	-5.25%	+2.36%	-5.43%	-1.93%	+0.73%	+7.40%	+3.25%	+4.75%	+3.98%	+5.58%	+6.15%	-8.48%	-11.64%	-2.49%	-6.96%	-21.32%

CORT

CORT fundamentals

CORT Q4 2025 Earnings

Earnings Call

You can ask Aime

CORT

CORT fundamentals

CORT Q4 2025 Earnings

Earnings Call

CORT Earnings Call Summary for Q4/20255:00 PM on Feb 24, 2026

CORT Earnings Call Summary for Q3/20255:00 PM on Nov 4, 2025

CORT Earnings Call Summary for Q2/20255:00 PM on Jul 31, 2025

CORT Earnings Call Summary for Q1/20255:00 PM on May 5, 2025

CORT Earnings Call Summary for Q4/20245:00 PM on Feb 26, 2025

You can ask Aime